Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.

Foster City, California-based SutroVax closed on a Series D preferred stock financing worth $110 million, which was co-led by new investors RA Capital Management and Janus Henderson Investors.

Social distancing measures for COVID-19 are having an impact on the planned merger of Mylan and Pfizer’s off-patent business, Upjohn.

Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.

Rubius Therapeutics is minimizing the focus on the company’s rare disease pipeline and taking greater aim at developing treatments for cancer and autoimmune diseases.

One of the companies working on the cutting edge of the field of gene silencing is Pasadena, California-based Arrowhead Pharmaceuticals, which expectS 2020 to be a real inflection point.

Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach, as the company has a pipeline spanning both in vivo and ex vivo therapies to address severe and life-threatening diseases.

Revolution Medicines snagged $238 million through an initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including lead clinical candidate.

GlaxoSmithKline outlined a plan to split the company into two entities over the next two years.

Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.